WESTCHESTER, Ill., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions, announced today that its board of directors has declared a quarterly dividend of $0.82 per share on the Company’s common stock. The quarterly dividend will be payable on Jan. 20, 2026, to stockholders of record at the close of business on Jan. 2, 2026. For additional information about Ingredion Incorporated, including investor relations, financial updates, and upcoming ...

CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on December 11, 2025 (the “Grant Date”), the Company’s Board of Directors granted non-qualified stock options to purchase an a ...

Kfar Saba, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today announced the successful demonstration of its advanced DefendAir counter-UAS (C-UAS) system at a high-profile event organized by the International Defense Cooperation Directorate (SIBAT) at the Israel Ministry of Defense’s (IMOD) demonstration fa ...

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today provides an update on the regulatory review in the EU for blarcamesine to treat early Alzheimer's disease. As ...

LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering of an aggregate of 10,666,667 shares of its common stock (or common stock equivalents in lieu thereof), Series F warrants to purchase up to 10,666,667 shares of com ...

NEWPORT BEACH, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze” or the “Company”), a global leader in creator-powered commerce, today announced that its Special Meeting of Stockholders, originally scheduled to be held on December 10, 2025, was convened and immediately adjourned due to the absence of a quorum required to conduct business. The Special Meeting has been adjourned to February 4, 2026, at 11:00 a.m. Eastern time. A notice of the reconvened meeting date ...

PIRAEUS, Greece, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Navios Maritime Partners L.P. (“Navios Partners”) (NYSE: NMM), an international owner and operator of dry cargo and tanker vessels, today announced senior leadership changes. Angeliki Frangou, Chairwoman and Chief Executive Officer stated “Today marks the beginning of an exciting new chapter as we strengthen the executive management team and continue our mission of being a leading player in the maritime industry through rigorous risk management, prudent cap ...

Core Insights - Alector, Inc. has appointed Neil Berkley as Chief Financial Officer (CFO), effective December 10, 2025, while he continues to serve as Chief Business Officer (CBO) [1][2] Company Overview - Alector is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, utilizing genetics, immunology, and neuroscience [3] - The company aims to address conditions such as Alzheimer's disease, Parkinson's disease, and frontotemporal dementia through its innovative product candidates [3] - Alector is developing the Alector Brain Carrier (ABC) platform to enhance therapeutic delivery across the blood-brain barrier, aiming for improved patient outcomes and cost reduction [3] Leadership Insights - Neil Berkley has over two decades of experience in corporate strategy, finance, business development, and operations within the biotech sector [2] - His leadership has been pivotal in advancing Alector's strategic priorities and strengthening partnerships since joining the company in 2024 [2] - Berkley's background includes founding two companies and serving on multiple biotech boards, showcasing his extensive industry experience [2]

Supported by Scientific Evidence Showing Tissue Repair Quality of Company’s ExosomesTORONTO and HAIFA, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-biotechnology company developing exosome-based therapies for central nervous system injuries, today announced meaningful progress in its long-term clinical-readiness strategy. The Company has begun the process of evaluating potential Israeli production partners ...

Kaldalón hf. (“Kaldalón”) and FÍ fasteignafélag slhf. (“FÍ fasteignafélag”) have signed Kaldalón’s purchase offer for all real estate assets owned by FÍ fasteignafélag. The property portfolio comprises 11 properties with a total floor area of approximately 25,200 square metres. All properties are located in the Greater Reykjavík area and include, among other things, a hotel, an embassy, a primary healthcare facility and office premises. Key assets within the portfolio include Hverfisgata 103, which houses a ...